Keywords: GlaxoSmithKline, Isisi Pharma, ISIS-TTRrx, Milestone, Amyloidosis, Theravance, Anoro Ellipta, COPD, USA, FDA

GSK pays $7.5 million milestone to Isis Pharma under antisense deal; says FDA accepts Anoro Ellipta NDA

Article | 20 February 2013

Print This

US biotech firm Isis Pharmaceuticals (Nasdaq: ISIS) says that it has earned a $7.5 million milestone payment from UK pharma giant ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in